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Over the past decade, inhibition of the kinase activities of oncogenic proteins using small molecules and
antibodies has been a mainstay of our anticancer drug development effort, resulting in several Food and Drug
Administration–approved cancer therapies. The clinical effectiveness of kinase-targeted agents has been
inconsistent, mostly because of the development of resistance. The expression and function of oncoproteins
and tumor suppressors are regulated by numerous posttranslational protein modifications including phosphorylation,
ubiquitination, and acetylation; hence, targeting specific posttranslational protein modifications provides for an
attractive strategy for anticancer drug development. The present review discusses the hypothesis that targeted
degradation of an oncoprotein may overcome many of the shortcomings seen with kinase inhibitors and that the
approach would enable targeted inhibition of oncogenic proteins previously thought to be undruggable.
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The molecular complexity of cancer is reflected by the ever-increasing
list of genetic drivers of oncogenesis. In preclinical models, the
targeted inhibition of oncogenic pathways has been an effective
strategy in many types of cancer; however, the clinical success of
these drugs has been limited to a handful of targets and diseases.
Because aberrant kinase activity is linked to oncogenesis, adenosine
triphosphate–competitive inhibitors such as erlotinib represent the
mainstay of our current drug development pipeline. Unfortunately,
many oncogenic targets are thought to be undruggable using these
traditional drug design strategies, and the development of drug
resistance to existing targeted agents is a significant problem. Novel
strategies to target oncogenic drivers are greatly needed.
X-ray crystallography, nuclear magnetic resonance spectroscopy, and
molecular modeling have elucidated the three-dimensional structures of
many protein targets. Insight into the structural basis of kinase function
as well as the structural requirements for protein-ligand and
protein-protein interactions has opened the door for novel therapeutic
strategies. The identification of specific protein domains involved in
chaperone binding, ubiquitination, and dimer formation allows for the
development of novel agents that target oncoprotein stability and
induce degradation. These strategies have the potential to overcome
resistance seen with traditional kinase inhibitors.
In this article, we will review previous attempts at targeting various
protein posttranslational modifications including phosphorylation.
We then present an argument that the targeted degradation of anoncoprotein has several advantages over the mere inhibition of kinase
activity as this strategy has the potential to affect the cellular processes
of a protein that are not related to kinase activity. Furthermore, we
describe how undruggable proteins such as KRAS may be targeted
with this approach.
Background: Targeting Posttranslational Modifications for
Cancer Therapy
Although several posttranslational modifications affect the function
of an oncoprotein, almost all drug development efforts have focused
on the altering the attachment of phosphate groups by protein
kinases. This protein modification controls many important aspects
of protein activity, localization, and stability. Many very successful
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using this strategy (Table 1). For example, imatinib (Gleevec,
Novartis) revolutionized the treatment of chronic myeloid leukemia
and gastrointestinal stromal tumors [1]. Also, epidermal growth factor
receptor (EGFR) inhibitors including erlotinib (Tarceva, Genentech)
have become standard of care for subsets of patients with non–small
cell lung cancer and colorectal cancer [2]. Serine/threonine kinase
inhibitors and multikinase inhibitors have also been developed.
Vemurafenib (Zelboraf, Daiichi Sankyo) is a serine/threonine kinase
inhibitor that is Food and Drug Administration (FDA) approved for
patients with metastatic BRAFV600E mutant melanoma [3]. Sorafenib
(Nexavar, Bayer) inhibits the serine/threonine kinase RAF and the
tyrosine kinases platelet-derived growth factor receptor and vascular
endothelial growth factor receptor. It has FDA approval for the
treatment of advanced-stage renal cell carcinoma and hepatocellular
carcinoma [4].
The concern with selective targeted agents is that parallel signaling
pathways can compensate for the inhibition of a single kinase and
resistant mutations can quickly develop. Conversely, with multitar-
geted kinase inhibitors, there are issues with off-target effects leading
to toxicity. Also, because multiple pathways are affected, there is a
poor understanding of the true mechanism of these agents in a
particular tumor, making it difficult to develop further improvements
in specificity or activity.
Besides phosphorylation, other posttranslational protein modifi-
cations have been identified as targets for cancer therapy. One of the
earliest attempts at this strategy was inhibition of RAS isoprenylation
by farnesyltransferase inhibitors [5]. More than 30 years ago, the
attachment of farnesyl side chains to RAS proteins (including H-, N-,
and K-RAS) was found to be critical for wild-type and mutant
oncogenic protein localization and function. Farnesyltransferase
inhibitors showed promise in preclinical tumor models; however,
they have failed in the clinic because of the presence of alternate
isoprenylation pathways through the geranyl side chain attachment.
Given the presence of multiple isoprenylation modifications, dual
inhibitors targeting both farnesylation and geranylation were tested;
however, this strategy showed increased toxicity as approximately 30
mammalian proteins are known to undergo similar posttranslational
modifications. A recent review [6] describes the many unsuccessful
attempts at targeting RAS. Given its important role in several types of
cancer, novel strategies are needed to target KRAS mutant-driven
tumors.
Similar to phosphorylation, protein acetylation has been exten-
sively explored as a strategy to target cancer. Histone deacetylase
(HDAC) inhibitors such as vorinostat (Zolinza) and romidepsin
(Istodax) are FDA approved for the treatment of cutaneous T-cell
lymphoma [7]. Recently, LBH589 (Panobinostat, Novartis) in
combination with dexamethasone and bortezomib was shown to
slow progression of multiple myeloma in a phase III trial. The
mechanism behind HDAC inhibitor cytotoxicity is complex and
poorly understood. One proposed mechanism is that HDAC
inhibition leads to increased expression of tumor suppressors,
although several other cellular processes are altered as well.
Chaperone proteins represent a unique class of therapeutic targets.
After translation, the chaperone machinery plays an important role in
protein homeostasis by facilitating nascent protein maturation and
folding. HSP90 is critical for the maintenance of more than 600
proteins including several oncoproteins. Even though highly potent
HSP90 inhibitors such as geldanamycin and its derivatives (17-AAGor 17-DMAG) (reviewed in [8]) have been extensively studied, no
HSP90 inhibitors are FDA approved because of their toxicity.
Next-generation HSP90 inhibitors, such as ganetespib [9], have
shown promise for improved tumor selectivity in preclinical models.
Preliminary results from an ongoing clinical trial suggest that the
single agent ganetespib has activity in a subset of advanced-stage non–
small cell lung carcinoma (NSCLC) patients [10]. Furthermore, a
phase IIB/III study evaluating the safety and therapeutic activity of
ganetespib in combination with docetaxel in NSCLC found that this
combination improved survival [11]. It is unclear why ganetespib is
less toxic than first-generation HSP90 inhibitors. It may be due to a
more tolerable dosing schedule or relatively selective degradation of
oncoproteins. Future studies will improve our understanding of how
to effectively use HSP90 inhibitors in patients.
Inducing Protein Degradation as an Attractive Alternative
to Inhibition
Resistance to kinase inhibitors is a major challenge limiting the
clinical effectiveness of these drugs. Single amino acid substitutions
can make a kinase inhibitor ineffective. Given that a tumor typically
contains a billion cells per cubic centimeter and the fact that tumors
cells are genetically unstable, it is likely that a resistance mutation will
be present. Prolonged exposure to a drug will select for the resistant
population. This phenomenon has been clearly demonstrated in non–
small cell lung cancer expressing EGFR with a threonine-790-
methionine (T790M) point mutation [12]. Careful analysis has
indicated that the T790M mutation is a de novo mutation, inferring
that TKI treatment selects for these cells. A drug that selectively
degrades a target should theoretically be effective in kinase inhibitor–
resistant and –sensitive cells.
One approach to eliminating a target rather than simply inhibiting
it is to deliver small interfering RNA (siRNA). Indeed, several studies
suggest that the reduction of a protein by an siRNA can be effective
for treating cancer. Reducing the amount of a specific protein has
certain advantages over inhibition of its activity as a protein’s physical
presence can serve critical functions beyond its catalytic activity. One
of the first examples of this concept came from the yeast
(Saccharomyces cerevisiae) protein Pbs2p. Both the kinase activity of
Pbs2p and its function as scaffolding were found to be equally
important in maintaining cellular osmolarity [13]. A recent review
article by Rauch et al. [14] identifies more than 70 kinases whose
catalytic activity and physical presence (mainly as scaffolding
proteins) are critical in disease pathogenesis. Among these kinases,
some of the most relevant to cancer are in the ErbB family which
includes EGFR and Her2. ERBB3 is a very interesting member of this
family as it has no kinase activity but can facilitate signal transduction
by forming a heterodimer with another family member [15].
Furthermore, a kinase-defective mutant of EGFR (K721M) can
activate downstream signaling with assistance of ErbB2 (Her2) after
EGF stimulation [16]. These findings demonstrate that ErbB family
members and other receptor tyrosine kinases have important cellular
functions that are independent of kinase activity.
In addition to its scaffolding role, EGFR has many other functions
beyond kinase activity. EGFR was recently found to protect cells from
autophagy by a kinase-independent mechanism [17]. Also, the
EGFRvIII mutant can sequester the proapoptotic protein PUMA in a
kinase independent manner, promoting drug resistance [18].
Furthermore, in genetically engineered mouse models, EGFR
knockout is embryonically lethal [19], whereas transgenic mice
Table 1. List of Posttranslational Protein Modifications and FDA-Approved Agents as Anticancer Agents
Agent Target Disease Site Clinical Results Year FDA Approval
Tyrosine kinase inhibitors
Trastuzumab HER2 Metastatic HER2+ gastric cancer OS improved 11.7 to 13.1 mo 2010
Adjuvant therapy for HER2+, LN+ breast cancer DFS HR 0.48 2006
Metastatic HER2+ breast cancer TTP improved 4.6 to 7.6 mo 1998
Imatinib BCR-ABL c-Kit Adjuvant therapy for GIST Improved OS with 36 mo vs 12 mo HR 0.45 2008/2012
Unresectable or metastatic GIST ORR 38% 2002
CML Hematologic response 88% (chronic phase) 2001
Gefitinib EGFR NSCLC ORR 10.6% 2003
Two failed clinical trials Revoked 2005
Bevacizumab VEGFR Metastatic cervical cancer OS improved 12.9 to 16.8 mo 2014
Platinum-resistant ovarian cancer PFS improves 3.4 to 6.8 mo 2014
Renal cell carcinoma PFS improved 5.4 to 10.2 mo 2009
Refractory high-grade glioma No phase III data with
non–bevacizumab-containing arm
2009
Metastatic renal cell carcinoma PFS improved 5.4 to 10.2 mo 2009
Metastatic breast cancer PFS improved 5.8 to 11.3 mo 2008
No survival benefit Revoked 2011
Nonsquamous NSCLC OS improved 10.3 to 12.3 mo 2006
Second-line metastatic colorectal cancer OS improved 10.8 to 13.0 mo 2006
First-line metastatic colorectal cancer ORR improved 35% to 45% 2004
Cetuximab EGFR K-ras wild type, EGFR-expressing
metastatic colorectal cancer
OS improved 19.5 to 23.5 mo
in K-ras wild-type tumors
2012
Metastatic head and neck cancer Improved OS 18.2 to 19.1 mo 2012
Head and neck cancer with radiation therapy OS improved 29.3 to 49.0 mo 2006
EGFR-expressing metastatic colorectal cancer ORR 23% combined with irinotecan 2004
Erlotinib EGFR Metastatic NSCLC with EGFR mutation Improved PFS 5.2 to 10.4 mo 2013
Maintenance treatment of NSCLC Improved PFS HR 0.71 2010
Unresectable pancreatic cancer OS improved 6.0 to 6.4 mo 2005
Refractory NSCLC OS improved 4.7 to 6.7 mo 2004
Dasatinib Multityosine kinase inhibitor Chronic-phase CML, Philadelphia
chromosome positive (Ph+)
Complete cytogenic response
improved 66.2% to 76.8%
2010
Refractory CML and ALL, Ph+ No phase III data 2006
Panitumumab EGFR EGFR-expressing metastatic colorectal cancer PFS improved 60 to 96 d 2006
Sunitinib Multikinase
(VEGFR, PDGFR, KIT, FLT3, RET)
Pancreatic neuroendocrine tumor PFS improved 5.4 to 10.2 mo 2011
Renal cell carcinoma ORR 25.5%-36.5% 2006
GIST TTP improved 6 to 27 wk 2006
Lapatinib HER-2 ER/PR+, HER2+ breast cancer PFS improved 13 to 35 wk 2010
HER2+ breast cancer TTP improved 18 to 24 wk 2007
Pazopanib VEGFR Advanced soft tissue sarcoma PFS improved 1.6 to 4.6 mo 2012
Advanced renal cell carcinoma PFS improved 4.2 to 9.2 mo 2009
Vandetanib VEGFR, EGFR Medullary thyroid cancer ORR improved 1% to 44% 2011
Crizotinib c-Met, anaplastic lymphoma kinase (ALK) ALK-positive NSCLC PFS improved 3.0 to 7.7 mo 2011/2013
Axitinib VEGFR Renal cell carcinoma Improved PFS 4.7 to 6.7 mo 2012
Bosutinib Bcr-Abl, Src-family kinases CML/ALL Ph+ No phase III data 2012
Cabozantinib Pan-tyrosine kinase inhibitor Metastatic medullary thyroid cancer PFS improved 4.0 to 11.2 mo 2012
Ponatinib Multikinase inhibitor CML/ALL Ph+ Phase III trial stopped 2012
Regorafenib Multikinase inhibitor GIST PFS improved 0.9 to 4.8 mo 2013
Refractory metastatic colorectal cancer Improved OS 5.0 to 6.4 mo 2012
Afatinib EGFR, HER2, HER4 Metastatic NSCLC with mutant EGFR PFS improved 6.9 to 11.1 mo 2013
Ibrutinib Burton’s tyrosine kinase CML ORR 58.3% 2014
Mantle cell lymphoma ORR 69% 2013
Ceritinib ALK ALK-positive metastatic NSCLC ORR 54.6% 2014
Ramucirumab VEGFR Gastric cancer OS improved 3.8 to 5.2 mo 2014
Metastatic NSCLC OS improved 9.1 to 10.6 mo 2014
Serine/threonine kinase inhibitors
Vemurafenib BRAFV600E Melanoma V600E mutant PFS improved 1.6 to 5.3 mo 2011
Trametinib MEK1, MEK2 Melanoma BRAF V600E/V600K mutant PFS improved 1.5 to 4.8 mo 2013
Dabrafenib BRAF, CRAF Melanoma BRAF V600E mutant PFS improved 2.7 to 5.1 mo 2013
Other kinase inhibitors
Sorafenib Multikinase inhibitor
(BRAF, VEGFR, PDGFR, FLT3, KIT)
Differentiated thyroid cancer PFS improved 5.8 to 10.8 mo 2013
Hepatocellular carcinoma OS improved 7.9 to 10.7 mo 2007
Renal cell carcinoma PFS improved 84 to 167 d 2005
Temsirolimus mTOR Renal cell carcinoma Improved PFS 3.1 to 5.5 mo 2007
Everolimus mTOR HER2-negative breast cancer PFS improved 3.2 to 7.8 mo 2012
Pancreatic neuroendocrine tumor PFS improved 4.6 to 11.0 mo 2011
Renal cell carcinoma PFS improved 1.9 to 4.9 mo 2009
Idelalisib Phosphoinositide-3 kinase Relapsed CLL PFS HR 0.18 2014
SLL ORR 58%
Follicular NHL ORR 54%
(continued on next page)
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TABLE 1 (continued)
Agent Target Disease Site Clinical Results Year FDA Approval
HDAC inhibitors
Vorinostat HDAC Cutaneous T-cell lymphoma ORR 30% 2006
Romidepsin HDAC Cutaneous T-cell lymphoma ORR 34-35% 2009
Belinostat HDAC Refractory peripheral T-cell lymphoma ORR 25.8% 2014
Panobinostat HDAC Refractory multiple myeloma PFS improved 5.8 to 10.6 mo 2015
Proteasome inhibitors
Bortezomib Proteasome Mantle cell lymphoma PFS improved 14 to 25 mo 2014
Multiple myeloma ORR 28% 2003
Carfilzomib Proteasome inhibitor Multiple myeloma ORR 23% 2012
PARP inhibitors
Olaparib PARP Ovarian cancer with germline BRCA mutation ORR 34% 2014
DOR: duration of response; ORR: overall response rate; PFS: progression-free survival; TTP: time to progression.
HR = Hazard Ratio DFS = Disease Free Survival OS = Overall Survival.
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defects [20]. Also, mice that express a kinase-inactive form of EGFR
(V765G-EGFR) are fertile and show a significant reduction in
intestinal polyps when crossed with APCMin mice compared with
APCMin mice carrying wild-type EGFR. These findings suggest that
EGFR kinase activity is important for tumorigenesis, but its physical
presence is essential for cell survival. Along these lines, in patients with
colorectal cancer, EGFR expression correlates with prognosis but not
with response to EGFR inhibitors such as cetuximab. We recently
reported our finding that degradation of EGFR is more efficacious
than treatment with small molecule inhibitors and that this strategy can
overcome resistance from an acquired EGFR mutation (T790M) [21].
We discuss this strategy in more detail later in this review.
Proteosome Inhibitors as Anticancer Agent
So far, the most successful drug targeting protein degradation is
bortezomib (Velcade, Millennium Pharmaceuticals). It is approved
for use in patients with multiple myeloma and non-Hodgkin’s
lymphoma. Bortezomib binds to the catalytic site of the 26S
proteasome, ultimately inhibiting the degradation of proteins.
Because the proteasome degrades most cellular proteins, this drug
class has many side effects including peripheral neuropathy and
myelosuppression [22]. A proposed mechanism of bortezomib’s
anticancer activity is the attenuation of IκB degradation which
promotes inactivation of NF-κB. However, the true mechanism
behind this drug’s actions is poorly understood as countless proteins
are affected by proteasome inhibition.
Given the lack of target specificity seen with proteasome inhibitors,
more selective approaches that target the degradation of a specific
oncoprotein or tumor suppressor are needed. One way to accomplish
this goal is to target protein ubiquitination or neddylation processes.
A novel inhibitor of neddylation, pevonedistat (MLN4924), is
currently in clinical trials for hematologic malignancies and
melanoma. Similarly, the E3 ubiquitin ligase MDM2 has been
targeted in patients using the drug RO5045337A. Several recent
reviews discuss these efforts in more detail. Below, we discuss novel
approaches of targeting protein-protein interaction to target
oncogenes and tumor suppressors.
Targeting Ubiquitination-Mediated Protein Degradation
Ubiquitination-mediated protein degradation is an exciting target
for cancer therapy. The ubiquitination cascade consists of three
enzyme groups: E1 is a group of ubiquitin-activating enzymes, E2 is a
group of ubiquitin-conjugating enzymes, and E3 is a group of
ubiquitin ligases. This cascade regulates the addition of ubiquitinmoieties to specific proteins within a cell, leading to protein
degradation. By altering these pathways, one can potentially
manipulate the degradation of a protein. An example of this strategy
is the use of 5-deazaflavin derivatives to inhibit the ubiquitin ligase
MDM2, resulting in decreased degradation of p53, a tumor
suppressor [23]. Although 5-deazaflavin derivatives inhibit
MDM2-mediated p53 ubiquitination, they have poor substrate
selectivity as they target a number of other kinases. An alternative
strategy being studied is the use of Nutlins (particularly Nutlin-3)
to disrupt the interaction between p53 and MDM2 [24]. Nutlins
are currently in clinical trials for pediatric cancers containing
wild-type p53.
Like p53, a reduction in p27 levels has been correlated with a poor
prognosis in many types of cancer. Mechanistic studies indicate that
the loss of p27 depends on SKP2 E3 ligase-mediated proteasomal
degradation. A recent report describes a small molecule capable of
disrupting a critical interaction between SKP2 with its partner SKP1
[25]. Similarly, the interaction of SKP2 with phosphorylated p27
requires the adapter protein CKS1 for degradation. Small molecule
inhibitors capable of disrupting the SKP2:CKS1 interaction have
been developed [26]. Another example of this strategy is targeting
PML, a known tumor suppressor. PML is downregulated in many
human malignancies because of enhanced ubiquitination-mediated
proteasomal degradation. Agents that manipulate PML ubiquitina-
tion are in development.
Similar to the downregulation of tumor suppressors, the
overexpression of oncoproteins is critical for cancer development
and progression. The amount of a specific protein in a cell depends on
the rate it is synthesized and its stability or half-life. So far, efforts to
target an oncoprotein’s stability have been limited. As discussed
above, we believe that the physical presence of an oncoprotein,
independent of its activity, can promote cancer progression.
Therefore, inducing degradation of an oncogenic protein, as opposed
to mere inhibition of its activity, is a promising strategy. A better
understanding of the factors responsible for the stability of
oncoproteins is needed to accomplish this.
A New Approach of Targeted Oncoprotein Degradation
EGFRDegradation: Disruption Of Homo- AndHeterodimerization. We
have studied the selective degradation of EGFR as a novel strategy to target
EGFR-driven tumors. Under physiological conditions, EGFR is stable with
a half-life greater than 12 hours. Its stability depends on the ability to form
homo- or heterodimers as EGFR is highly unstable in its monomer state.
When inactive, EGFR can form a dynamic heterocomplex with the
chaperone protein HSP90, promoting stability [27]. Upon stimulation by
Figure 1.Disruption of protein-protein interactions to induce oncoproteins degradation. (A) Disruptin (D), a peptide containing aneight–amino
acid stretch of human EGFR, is capable of disrupting the protein:protein interactions between EGFR:HSP90 and EGFR homodimers. These
interactions are critical formaintainingEGFRstability. In the presenceof high levels of EGF, as seen in the tumormicroenvironment, treatment
with Disruptin causes rapid degradation of EGFR. In preclinical models, treatment with Disruptin induces regression of EGFR-dependent
tumors including those resistant to TKIs. (B) Interaction between the SMURF2:UBCH5 protein complex and β-TrCP1 plays a critical role in the
maintenance of KRAS protein stability. The SMURF2:UBCH5 complex polyubiquitinates and degrades β-TrCP1, which indirectly protects
KRAS from degradation.We found that the disruption of the SMURF2:UBCH5 complex can promote β-TrCP1 accumulation, leading to rapid
KRAS degradation.
Neoplasia Vol. 17, No. 9, 2015 Oncoprotein Degradation for Cancer Therapy Ray et al. 701various growth factors, EGFR is phosphorylated and dissociates withHSP90
to form a homodimer with another EGFR molecule or a heterodimer with
another EGFR family member (such as ErbB-2, -3, or -4) or related tyrosine
kinase (such as c-Met). Based on these findings, we identified a critical eight–
amino acid stretch (amino acids 768-SVDNPHVC-775) that lies within the
αC-β4 loop region of the EGFR kinase domain corresponding to the
binding region of HSP90 [28]. We found that mutating the first six amino
acids in this sequence disrupts EGFR homo- and heterodimerization,
making the protein highly unstable (half-life b3 hours). Using this
knowledge, we developed a peptide named Disruptin (Figure 1A), which
inhibits dimerization of EGFR, leading to rapid degradation. As cancer cells
have higher levels of activated EGFR than normal tissue, Disruptin
preferentially targets tumor cells expressing EGFR. Furthermore,
Disruptin has therapeutic efficacy in preclinical xenograft models
carrying the T790M mutation which makes tumors resistant to
erlotinib. This demonstration of selective EGFR degradation with the
peptide Disruptin represents a novel therapy for EGFR-driven tumors,
including those that are TKI resistant [28].
EGFR Degradation: Targeting Receptor Trafficking. Receptor
trafficking also plays a critical role in determining the fate of EGFR
molecules. Monoubiquitination and polyubiquitination of EGFR are
involved in its stability, localization, and functionality. In addition to
its ability to signal from the cell membrane, EGFR is also involved insignal transduction after it is endocytosed. The endocytosed receptor
can be recycled back to the cell membrane, or it can be trafficked to
the multivesicular bodies for lysosomal degradation. Factors involved
in EGFR trafficking can be categorized into two groups: 1) factors
that promote receptor recycling and 2) factors that promote EGFR
endocytosis and degradation. Among the trafficking factors that
promote receptor stability, Vav proteins (guanine nucleotide
exchange factors) have been shown to positively regulate EGFR
signaling by attenuating receptor internalization and degradation.
Similarly, SGEF and DYRK1A can protect EGFR from degradation
by delaying lysosomal sorting. Factors like Odin/ANKS1A also
interact with EGFR, increasing receptor recycling. In contrast, Ephrin
A5 promotes EGFR degradation by cooperating with c-CBL, an E3
ligase known to polyubiquitinate this protein. Also, Presenilin, a
component of gamma-secretase protease complex, causes EGFR
degradation indirectly by negatively regulating the expression and
activity of the RING-type ubiquitin ligase Fbw7. All of these
molecules represent novel molecular targets for EGFR-driven tumors.
Because ubiquitination plays an important role in EGFR
endocytosis, trafficking, and lysosomal degradation, various ubiquitin
ligases and deubiquitinating enzymes have been shown to regulate
EGFR stability. The most extensively studied E3 ubiquitin ligase
responsible for EGF-mediated EGFR polyubiquitination is c-CBL.
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polyubiquitination and degradation of EGFR [29,30]. We have
recently identified that the HECT-type E3 ubiquitin ligase SMURF2
directly interacts with EGFR. SMURF2’s ubiquitin ligase activity is
critical for maintaining EGFR protein stability [31]. Similar to
SMURF2, deubiquitinating enzymes such as USP18 and USP2A
protect EGFR from degradation. USP18 negatively regulates
the expression of a microRNA (miR-7) which blocks EGFR
translation by binding to the 3’-UTR of the EGFR transcript.
USP2A antagonizes EGFR endocytosis via deubiquitination.
Knowledge of the factors responsible for maintaining EGFR protein
stability will allow for the development of novel drugs targeting this
important receptor.
Downregulation of Mutant KRAS Protein: siRNA
Mutant KRAS has a high prevalence in pancreatic (90% KRAS
mutant), colorectal (50% mutant), and lung (30% mutant) cancers.
Effective treatment strategies are greatly needed for patients with
KRAS-driven tumors. Direct inhibition of this protein is not feasible
because of high intracellular GTP concentrations (micromolar)
compared with the picomolar affinity between KRAS and GTP.
Because KRAS acts as an on/off switch for multiple signaling
pathways, the predominant strategy for targeting mutant KRAS
tumors has focused on inhibiting downstream pathways including
RAF-MEK-ERK and PI3K-AKT-mTOR. These approaches have
had limited success because of the activation of compensatory
signaling. In contrast, various studies using mutant KRAS–specific
siRNA-mediated knockdown have shown promise.
Early attempts using either an anti-KRAS ribozyme [32] or
shRNA-mediated knockdown of KRAS [33] demonstrated tumor
growth delay of mutant KRAS-driven NSCLC. However, in these
studies, compensatory activation of STAT3 and EGFR signaling was
noted, suggesting that targeting mutant KRAS alone may not be
sufficient. Along this point, a recent report demonstrated better in
vivo tumor control when mutant KRAS siRNA was combined with
either RAF or PI3K siRNAs [34]. These studies confirm the
proof-of-principle that siRNA-mediated physical ablation of mutant
KRAS is an attractive therapeutic strategy; however, we believe that
the clinical success of these therapies depends on the long-term and
tumor-specific delivery of siRNA payloads, which remains a
challenge. Recently, one such siRNA delivery system has been
developed, called Local Drug Eluter (LODER). LODER is able to
protect siRNA from degradation and promotes localized prolonged
siRNA release, an essential requirement for clinical success [35].
Using this delivery system, mutant KRAS siRNA (siG12D LODER)
was delivered in pancreatic tumor xenograft models successfully.
Such a system is currently being tested in a phase I (NCT01188785)
and a phase II (NCT01676259) clinical trial for unresectable locally
advanced pancreatic cancer patients.
Downregulation of Mutant KRAS Protein: Targeting
Ubiquitination Machinery
Targeting posttranslational modifications of KRAS is a promising
alternative to siRNA-based methods. Supporting this idea is a recent
report that identifies a small molecule capable of inhibiting KRAS
through its interaction with prenyl-binding protein PDEδ, a step
critical for KRAS localization to the endomembrane [36]. Our work
related to this strategy has focused on targeting the ubiquitination
machinery that regulates KRAS stability. Monoubiquitination ofmutant KRAS is known to enhance its activity, amplifying
downstream signaling [37]. Based on the mechanistic studies of
other proteins, we speculated that monoubiquitination competes
with β-TrCP1–mediated polyubiquitination to maintain RAS protein
levels. Interestingly, we observed that, under physiological conditions,
the GTP-bound active form of mutant KRAS has a similar half-life as
the GDP-bound inactive form of wild-type KRAS. Our observation is
in direct contrast with previous reports which show that an active
protein has a shorter half-life than its inactive form. We hypothesized
that this difference is due to enhanced monoubiquitination of the
mutant form of KRAS. Based on our prior work, we hypothesized
that the E3 ubiquitin ligase SMURF2 regulates the stability of
GTP-bound mutant KRAS. As expected, we found that the loss of
SMURF2 caused mutant KRAS to become highly unstable.
Although we discovered that SMURF2 ubiquitin ligase activity is
critical in maintaining mutant KRAS protein stability, we found that
SMURF2 does not monoubiquitinate mutant KRAS as hypothesized.
Instead, it indirectly protects mutant KRAS by polyubiquitinating
and degrading β-TrCP1 [38]. As a proof-of-principle study, we
showed that si/sh-RNA targeting of SMURF2 attenuates the growth
of mutant KRAS–driven tumors. Although the finding that SMURF2
silencing can degrade mutant KRAS and block the growth of mutant
KRAS–dependent tumors is encouraging, direct inhibition of
SMURF2 ubiquitin ligase activity is not a viable strategy because of
the critical importance of SMURF2 in mitosis [39]. We further found
that SMURF2 can monoubiquitinate its partner ubiquitin conjugating
enzyme (E2) UBCH5 to form an E3:E2 complex required for β-TrCP1
degradation. These findings suggest that the SMURF2:UBCH5
complex is critical in maintaining mutant KRAS protein stability
and could be explored to develop the novel anti-KRAS strategy
proposed in Figure 1B.
Future Directions
Inhibition of oncogenic kinase activity has led to the discovery and
development of novel therapies that benefit patients. However, kinase
inhibition has significant limitations including the emergence of drug
resistance leading to limited therapeutic durability. Targeting protein
stability is an interesting alternative strategy that is potentially applicable to
any oncoprotein or tumor suppressor. Strategies such as disrupting
protein-protein interactions to destabilize an oncoprotein or to stabilize a
tumor suppressor protein are in the early phases of development. Although
targeting protein-protein interactions using synthetic agents is challenging,
recent advancements in structural and computational proteomics allow us
to identify novel synthetic mimetics capable of disrupting specific
protein-protein interaction to induce oncoprotein degradation. Such an
approach can abolish the presence of an oncoprotein, which, in theory, can
overcome resistance to kinase inhibitors. Future studies will determine if
this approach can improve the outcomes of patients.
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